Evidence map›Paper›PMID 33025985›Full record

ReviewChemical communications (Cambridge, England)2020

Synthesis and biological study of the phomopsolide and phomopsolidone natural products.

Alhanouf Z Aljahdali, Kathryn A Foster, George A O'Doherty

Abstract readReview
In one paragraph

Review in Chemical communications (Cambridge, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alhanouf Z AljahdaliDept. of Chemistry and Chem. Bio., Northeastern Univ., Boston, MA 02115, USA. g.odoherty@neu.edu.
Kathryn A Foster
George A O'Doherty

Funding

Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogensR21AI142040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$476k
Fusidic acid derivatization to enhance entry into Gram-negative pathogensR21AI146485 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$475k
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogensR03AI144196 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$183k
NIAID NIH HHS R03 AI144196NIAID NIH HHS R21 AI142040NIAID NIH HHS R21 AI146485
6 · The paper itself

Abstract

The complete history of the syntheses and biological activities of the phomopsolide and phomopsolidone classes of natural products is reviewed. These efforts include the successful synthesis of four of the five phomopsolide natural products, two of the four phomopsolidone natural products and two analogues of phomopsolide E, including the 7-oxa and 7-aza analogues. In addition, the utility of these synthetic efforts to enable the initial structure activity relationship studies for these classes of natural products is also covered.

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsBacteriaBiological ProductsCell ProliferationFemaleHumansMolecular StructurePyronesUterine Cervical NeoplasmsAnti-Bacterial AgentsAntineoplastic AgentsBiological ProductsPyrones

Identifiers

PMID33025985
PMCPMC7606950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.